Prosecution Insights
Last updated: April 19, 2026
Application No. 18/304,305

CELL CULTURE METHOD AND CELL CULTURE DEVICE USED WITH CELL CULTURE METHOD

Non-Final OA §103§112
Filed
Apr 20, 2023
Examiner
KNIGHT, TERESA E
Art Unit
1634
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Yamaguchi University
OA Round
1 (Non-Final)
65%
Grant Probability
Moderate
1-2
OA Rounds
3y 8m
To Grant
99%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allow Rate
307 granted / 475 resolved
+4.6% vs TC avg
Strong +50% interview lift
Without
With
+50.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
23 currently pending
Career history
498
Total Applications
across all art units

Statute-Specific Performance

§101
7.6%
-32.4% vs TC avg
§103
40.8%
+0.8% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
22.0%
-18.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 475 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of group I (claims 1-7) in the reply filed on Nov. 14, 2025 is acknowledged. Claims 8 and 9 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1-7 from the claim set dated April 20, 2023 are examined below. Priority The instant application claims foreign priority 35 U.S.C. 119(a)-(d) to Japanese Patent Application No. 2020-178448 filed on Oct. 23, 2020. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e). Failure to provide a certified translation may result in no benefit being accorded for the non-English application. Thus, the earliest possible priority for the instant application is Oct. 23, 2020. Information Disclosure Statement The information disclosure statements filed Apr. 20, 2023 and Nov. 13, 2025 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the IDSs have been considered by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-7 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites “a plurality of upper cell culture chamber and lower cell culture chambers…”. This phrase is indefinite because, while it is clear that there is a plurality of pairs, specifically what is paired is unclear, as the claim could be interpreted as the pairs being (1) upper chamber paired with lower chamber or (2) upper chamber paired with upper chamber to create a pair and lower chamber paired with lower chamber to create a pair. While the drawings and the specification appear to support the (1) interpretation, the language of the claim requires clarification. It is recommended that the claim be amended to recite “…a plurality of cell culture chambers, each of the plurality comprising a pair consisting of an upper cell culture chamber and a lower cell culture chamber…” and the rest of the claim being amended to be consistent with this recitation. Claim 1 further recites that the upper cell culture chambers are “coupled and integrated” and the lower cell culture chambers are “coupled and integrated”. This term is indefinite as it is unclear what the culture chambers are coupled and integrated with. If the cell culture chambers are coupled and integrated with one another, that should be recited. Claims 2-7 do not correct this indefiniteness and are rejected on that basis. Claims 2 and 3 are further rejected as each recites “…through-holes each being the inner wall” (through-holes (33d), (35c), (29e)). This is indefinite because it can be interpreted as the through-holes = the inner wall, which is impossible. Further, it is unclear if what is intended is that the cell culture plate (33) or the bottom board (35a) (claim 2) or the cell culture plate (29) is the inner wall OR if the intention is for the through-holes to be in the inner wall (“through-holes being in the inner wall”). For the purposes of examination, prior art is being applied that will account for any of these limitation interpretations. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1 and 3 are rejected under 35 U.S.C. 103 as being unpatentable over the combination of Crespi et al. (U.S. Patent App. No. 2007/0269850, cited on IDS filed on April 20, 2023) in view of Mussi (U.S. Patent No. 5,665,596, cited on IDS filed on April 20, 2023). Crespi et al. teach a cell culture device for seeding cells on a filter that extends over a well of an analysis device, the device having an elastomer body that has first and second surfaces separated from one another by a flow passage. The flow passage penetrates the first and second surfaces and extends between them, and is detachably engaged to the outside surface of the well in a sealed state and a filter is formed so as to be at least partially surrounded by the flow passage. The filter may include holes with various dimensions and configurations. The device is useful for growing cells on an outer or inner surface of one of more than one filters. (paras. [0011], [0012], [0016], figs. 4-6, claim 1). Crespi et al. do not teach a cell culture chamber cover. Mussi teach an adaptor that is used with a cell culture insert, indicating that a cover is placed on top of the assembly so as to prevent contamination when culturing cells in a receptacle formed by placing the adaptor on a second end of the cell culture insert (col. 4, l. 50 – col. l. 19; fig. 2). It would have been obvious for one of ordinary skill in the art at the time of the effective filing date to have modified the device taught by Crespi et al. to incorporate including a cell culture chamber cover (as taught by Mussi) because it would have been obvious to combine prior art elements according to known methods to yield predictable results. Incorporating this modification would have led to predictable results with a reasonable expectation of success because both references are directed to devices for enabling sophisticated, multiple cell type and layers cell culture devices and, as Mussi teaches covering the cell culture device to prevent contamination, including a cover in the device taught by Crespi et al. would have been an obvious choice when employing the device in a cell culture context. With respect to claim 3, as Crespi et al. teach that the filter may have holes with various dimensions and placement, a person of ordinary skill would have further taken the step of covering the lower part of the analysis device (Fig. 4 of Crespi) to prevent leakage of culture solution from the through holes. Conclusion Claims 2, and 4-7 are free of prior art and should be allowable when the indefiniteness rejections are overcome. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TERESA E KNIGHT whose telephone number is (571)272-2840. The examiner can normally be reached Monday-Friday 9-4. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maria Leavitt can be reached at 571-272-1085. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TERESA E KNIGHT/Primary Examiner, Art Unit 1634
Read full office action

Prosecution Timeline

Apr 20, 2023
Application Filed
Feb 21, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12570953
TISSUE-ENGINEERED CONSTRUCTS
2y 5m to grant Granted Mar 10, 2026
Patent 12558316
METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPIDERMOLYSIS BULLOSA
2y 5m to grant Granted Feb 24, 2026
Patent 12547118
LENS-FREE HOLOGRAPHIC OPTICAL SYSTEM FOR HIGH SENSITIVITY LABEL-FREE MICROBIAL GROWTH DETECTION AND QUANTIFICATION FOR SCREENING, IDENTIFICATION, AND SUSCEPTIBILITY TESTING
2y 5m to grant Granted Feb 10, 2026
Patent 12516304
COMPOSITIONS AND METHODS FOR IMPROVED NUCLEASES
2y 5m to grant Granted Jan 06, 2026
Patent 12516294
METHOD FOR PRODUCING MESENCHYMAL STEM CELLS FROM LIVING BODY-DERIVED CELL SAMPLE CONTAINING MESENCHYMAL STEM CELLS
2y 5m to grant Granted Jan 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+50.4%)
3y 8m
Median Time to Grant
Low
PTA Risk
Based on 475 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month